Skip to main content
SpringerLink
Log in

Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects

  • Clinical Trials
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

To compare antisecretory effects of single doses of rabeprazole and esomeprazole.

Methods

Open, randomised, 2-way crossover, clinical pharmacology study. 24 healthy subjects (10 men; mean age 26.2 y) received a single dose of rabeprazole 20 mg or esomeprazole 40 mg, with a 14-day ‘washout’. Intragastric pH was recorded continuously from 24 h before to 24 h after dosing.

Results

Mean intragastric pH was higher after esomeprazole than rabeprazole during 0–5 h after dosing (P=0.0001); the reverse was true from 14–24 h (P=0.0002). Mean % time pH>3 and >4 was greater after esomeprazole than rabeprazole during 0–14 h (P=0.041 and 0.044), but the reverse was true during 14–24 h (P=0.0005 and 0.001). In the 0–24 h interval as a whole, there was no difference between treatments in mean pH or % time pH>3 or >4.

Conclusion

Single-dose rabeprazole 20 mg was as effective as esomeprazole 40 mg in increasing intragastric pH and maintaining pH>3 and >4, despite the 2-fold difference in dose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jones DB, Howden CW, Burget DW, Kerr GD, Hunt RH (1987) Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut 28:1120–1127

    Article  PubMed  CAS  Google Scholar 

  2. Burget DW, Chiverton SG, Hunt RH (1990) Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 99:345–351

    PubMed  CAS  Google Scholar 

  3. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH (1992) Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51(Suppl 1):59–67

    Article  PubMed  Google Scholar 

  4. Hunt RH (1995) The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 9(Suppl 1):3–7

    PubMed  Google Scholar 

  5. Savarino V, Mela GS, Zentilin P, Mele MR, Vigneri S, Termini R, Di Mario F, Ferrana M, Malesci A, Belicchi M (1995) Once-daily bedtime dose of roxatidine and ranitidine in acute duodenal ulcer: a combined assessment of acid inhibitory activity and healing rate. Am J Ther 2:949–953

    Article  PubMed  Google Scholar 

  6. Robinson M (2004) Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors - overview and clinical implications. Aliment Pharmacol Ther 20(Suppl 6):1–10

    Article  PubMed  CAS  Google Scholar 

  7. Gardner JD, Perdomo C, Sloan S, Hahne WF, Barth JA, Rodriguez-Stanley S, Robinson M (2002) Integrated acidity and rabeprazole pharmacology. Aliment Pharmacol Ther 16:455–464

    Article  PubMed  CAS  Google Scholar 

  8. Warrington S, Baisley K, Boyce M, Tejura B, Morocutti A, Miller N (2002) Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 16:1301–1307

    Article  PubMed  CAS  Google Scholar 

  9. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL (2003) Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 17:1507–1514

    Article  PubMed  CAS  Google Scholar 

  10. Lind T, Havelund T, Lundell L, Glise H, Lauritsen K, Pedersen SA, Anker-Hansen O, Stubberod A, Eriksson G, Carlsson R, Junghard O (1999) On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomised trial. Aliment Pharmacol Ther 13:907–914

    Article  PubMed  CAS  Google Scholar 

  11. Talley NJ, Venables TL, Green JRB, Armstrong D, O’Kane KPJ, Giaffer M, Bardhan KD, Carlsson RGS, Chen S, Hasselgren GS (2002) Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 14:857–863

    Article  PubMed  CAS  Google Scholar 

  12. Bytzer P, Blum A, De Herdt D, Dubois D; The Trial Investigators (2004) Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 20:181–188

    Article  PubMed  CAS  Google Scholar 

  13. Baisley KJ, Tejura B, Morocutti A, Miller NM, Warrington SJ (2001) Rabeprazole 10 mg is equivalent to esomeprazole 20 mg in control of gastric pH in healthy volunteers. Am J Gastroenterol 96(Suppl):S48

    Google Scholar 

  14. Rohss K, Lind T, Wilder-Smith C (2004) Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 60:531–539

    Article  PubMed  CAS  Google Scholar 

  15. Williams MP, Sercombe J, Hamilton MI, Pounder RE (1998) A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and serum gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 12:1079–1089

    Article  PubMed  CAS  Google Scholar 

  16. Bruley des Varannes S, Gharib H, Bicheler V, Bost R, Bonaz B, Stanescu L, Delchier JC, Bonnot-Marlier S (2004) Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects. Aliment Pharmacol Ther 20:899–907

    Article  PubMed  CAS  Google Scholar 

  17. Morozov SV, Tsodikova OM, Isakov VA, Gushchin AE, Shipulin GA (2003) Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors. Eksp Klin Gastroenterol 6:58–63 [in Russian]

    PubMed  Google Scholar 

  18. Besancon M, Simon A, Sachs G, Shin JM (1997) Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 272:22438–22446

    Article  PubMed  CAS  Google Scholar 

  19. Kromer W, Kruger U, Huber R, Hartmann M, Steinijans VW (1998) Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology 56:57–70

    Article  PubMed  CAS  Google Scholar 

  20. Richardson P, Hawkey CJ, Stack WA (1998) Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 56:307–335

    Article  PubMed  CAS  Google Scholar 

  21. Horn J (2000) The proton-pump inhibitors: similarities and differences. Clin Ther 22:266–280

    Article  PubMed  CAS  Google Scholar 

  22. Horn J (2004) Review article: relationship between the metabolism and efficacy of proton pump inhibitors-focus on rabeprazole. Aliment Pharmacol Ther 20(Suppl 6):11–19

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hammersmith Medicines Research, Central Middlesex Hospital, Acton Lane, London, NW10 7NS, UK

    Steve Warrington, Kathy Baisley, Kate Dunn & Malcolm Boyce

  2. Eisai Ltd, 3 Shortlands, Hammersmith International Centre, Hammersmith, London, W6 8EE, UK

    Anna Morocutti

Authors
  1. Steve Warrington
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathy Baisley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kate Dunn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Malcolm Boyce
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anna Morocutti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steve Warrington.

Additional information

Supported by Eisai Ltd., London, UK

Rights and permissions

Reprints and permissions

About this article

Cite this article

Warrington, S., Baisley, K., Dunn, K. et al. Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects. Eur J Clin Pharmacol 62, 685–691 (2006). https://doi.org/10.1007/s00228-006-0148-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-006-0148-5

Keywords

Search

Navigation